(Q39343520)

11 September 2017

Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor (English)

1 reference

11 September 2017

Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor (English)

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

8 October 2023

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

8 October 2023

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

8 October 2023

author name string

J. R. Seibold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6365102

8 October 2023

A. H. Jageneau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6365102

8 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6365102

8 October 2023

publication date

1 February 1984

1 reference

full work available at URL

11 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.1780270204

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

https://onlinelibrary.wiley.com/doi/full/10.1002/art.1780270204

8 October 2023

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

8 October 2023

published in

Arthritis & Rheumatology

1 reference

11 September 2017

Arthritis and Rheumatism

27

2

139–46

February 1984

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6365102

8 October 2023

volume

27

1 reference

11 September 2017

2

1 reference

11 September 2017

139-146

1 reference

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

11 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FART.1780270204

Vascular Disease in Progressive Systemic Sclerosis (Scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780270204

Scleroderma-like lesions and the carcinoid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780270204

Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Drug therapy: vasodilator drugs in peripheral vascular disease

8 October 2023

4

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Raynaud's disease, Raynaud's phenomenon, and serotonin.

8 October 2023

5

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine

8 October 2023

6

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Response to serotonin and its antagonists in patients with rheumatoid arthritis and related diseases

8 October 2023

7

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors

8 October 2023

8

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist

8 October 2023

10

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Wide-field capillary microscopy

8 October 2023

12

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

The 1982 revised criteria for the classification of systemic lupus erythematosus

8 October 2023

13

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

8 October 2023

14

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

8 October 2023

19

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy

8 October 2023

20

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis

8 October 2023

21

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

The Journal of Rheumatology

8 October 2023

22

9

289

Maricq

1982

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

THE NERVE NETWORK OF THE SKIN IN DIFFUSE SCLERODERMA AND CLINICALLY SIMILAR CONDITIONS

8 October 2023

24

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

The kidney in progressive systemic sclerosis: a prospective study

8 October 2023

25

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis

8 October 2023

26

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon

8 October 2023

27

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

5-hydroxytryptamine: a cytospecific growth stimulator of cultured fibroblasts

8 October 2023

29

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Serotonin and Ribonucleic Acid and Collagen Metabolism of Fibroblasts in Vitro

8 October 2023

30

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Association of functioning carcinoid syndrome and scleroderma. I. Case report

8 October 2023

32

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate

8 October 2023

34

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

URINARY 5-HYDROXYINDOLEACETIC ACID EXCRETION IN SCLERODERMA

8 October 2023

35

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Urinary excretion of the serotonin metabolite, 5-hydroxyindoleacetic acid, in various clinical conditions

8 October 2023

36

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

5-Hydroxytryptamine and tryptamine pathways in scleroderma

8 October 2023

37

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Drug therapy: vasodilator drugs in peripheral vascular disease

8 October 2023

39

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

8 October 2023

40

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

Intraarterial Reserpine Administration in Raynaud Syndrome

8 October 2023

41

1 reference

https://api.crossref.org/works/10.1002/ART.1780270204

8 October 2023

Identifiers

1 reference

11 September 2017

1 reference